<p>StockNews.com 的股票分析师在周六发布的一份报告中开始覆盖 Intra-Cellular Therapies (NASDAQ:ITCI - 获取免费报告) 的股票。该经纪公司对这家生物制药公司的股票给予了 “持有” 评级。</p>
<ul>
<li>MarketBeat 周回顾 – 01/13 - 01/17</li>
</ul>
<p>其他分析师最近也对该股票发布了报告。瑞穗证券将 Intra-Cellular Therapies 的股票评级从 “跑赢大盘” 下调至 “中性”，并在 2 月 24 日的研究报告中将其目标价从 140.00 美元下调至 132.00 美元。贝尔德 R W 在 1 月 13 日的研究报告中将 Intra-Cellular Therapies 的评级从 “强力买入” 下调至 “持有”。加拿大皇家银行在 1 月 22 日的报告中重新发布了 “行业表现” 评级，并将 Intra-Cellular Therapies 的目标价设定为 132.00 美元（上调自 108.00 美元）。派珀·桑德勒在 1 月 14 日的研究报告中重申了 “中性” 评级，并将 Intra-Cellular Therapies 的目标价上调至 132.00 美元（之前为 107.00 美元）。最后，Leerink Partners 在 1 月 13 日的研究报告中将 Intra-Cellular Therapies 的评级从 “强力买入” 下调至 “持有”。共有 11 位分析师对该股票给予了持有评级，5 位分析师给予了买入评级。根据 MarketBeat 的数据，Intra-Cellular Therapies 目前的平均评级为 “持有”，共识目标价为 106.23 美元。</p>
<p><strong>获取我们关于 ITCI 的最新研究报告</strong></p>
<h2>Intra-Cellular Therapies 股票表现</h2>
<ul>
<li>强生股票是否准备回报长期持有者？</li>
</ul>
<p>NASDAQ ITCI 周五开盘价为 131.87 美元。该公司的 50 日移动平均线为 129.62 美元，200 日移动平均线为 101.43 美元。Intra-Cellular Therapies 的 52 周低点为 64.09 美元，52 周高点为 131.98 美元。该公司的市值为 140.5 亿美元，市盈率为 -151.57，贝塔值为 0.69。</p>
<p>Intra-Cellular Therapies (NASDAQ:ITCI - 获取免费报告) 最近在 2 月 21 日发布了季度财报。这家生物制药公司报告的每股收益为（0.16）美元，低于分析师的共识预期（0.08）美元，差距为（0.08）美元。该季度的收入为 1.9922 亿美元，而分析师的预期为 2.0508 亿美元。Intra-Cellular Therapies 的净利润率为 -14.07%，股本回报率为 -9.93%。平均而言，卖方分析师预测 Intra-Cellular Therapies 在当前年度的每股收益为 -0.64。</p>
<h2>机构投资者对 Intra-Cellular Therapies 的看法</h2>
<ul>
<li>百时美施贵宝的大额收购：在 2 笔生物技术交易中达 181 亿美元</li>
</ul>
<p>几家大型投资者最近买入和卖出了该公司的股票。MassMutual Private Wealth &amp; Trust FSB 在第一季度将其在 Intra-Cellular Therapies 的持股增加了 124.3%。MassMutual Private Wealth &amp; Trust FSB 目前拥有 240 股该生物制药公司的股票，价值 32,000 美元，此前在上个季度又购买了 133 股。威灵顿管理集团在第四季度将其在 Intra-Cellular Therapies 的持股增加了 1.6%。威灵顿管理集团目前拥有 1,033,743 股该生物制药公司的股票，价值 86,338,000 美元，此前在此期间又收购了 16,096 股。Wealth Enhancement Advisory Services LLC 在第四季度将其在 Intra-Cellular Therapies 的持股增加了 36.3%。Wealth Enhancement Advisory Services LLC 目前拥有 12,010 股该生物制药公司的股票，价值 1,003,000 美元，此前在上个季度又购买了 3,200 股。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度购买了 Intra-Cellular Therapies 的新股份，价值约 7,951,000 美元。最后，GF Fund Management CO. LTD. 在第四季度购买了 Intra-Cellular Therapies 的新股份，价值约 186,000 美元。机构投资者持有该公司 92.33% 的股票。</p>
<h2>关于 Intra-Cellular Therapies</h2>
<p>(获取免费报告)</p>
<p>Intra-Cellular Therapies, Inc 是一家生物制药公司，专注于发现、临床开发和商业化小分子药物，主要针对神经精神和神经系统疾病的医疗需求，通过靶向美国中枢神经系统 (CNS) 的细胞内信号机制。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Intra-Cellular Therapies</li>
<li>投资旅游股票的好处</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>顶级生物技术股票：探索创新机会</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>电动车股票及其盈利方式</li>
<li>波音在 3 月获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Intra-Cellular Therapies 吗？</h2>
<p>在你考虑 Intra-Cellular Therapies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前... 而 Intra-Cellular Therapies 并不在名单上。</p>
<p>虽然 Intra-Cellular Therapies 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ITCI

<p>Intra-Cellular Therapies（纳斯达克代码：ITCI）获得了 StockNews.com 的 “持有” 评级，该公司最近开始对该股票进行覆盖。其他分析师也调整了他们的评级，瑞穗将其下调至 “中性”，贝尔德将其下调至 “持有”。该股票的平均评级目前为 “持有”，共识目标价为 106.23 美元。该公司报告的季度每股亏损为 0.16 美元，未能达到预期，市值为 140.5 亿美元</p>

<p>Stock analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a report released on Saturday. The brokerage set a &#34;hold&#34; rating on the biopharmaceutical company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的股票分析师在周六发布的一份报告中开始覆盖 Intra-Cellular Therapies (NASDAQ:ITCI - 获取免费报告) 的股票。该经纪公司对这家生物制药公司的股票给予了 “持有” 评级。</p>
</div><ul>
<li>MarketBeat Week in Review – 01/13 - 01/17</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 01/13 - 01/17</li>
</ul>
</div><p>Other analysts have also recently issued reports about the stock. Mizuho cut shares of Intra-Cellular Therapies from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and reduced their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Baird R W lowered Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, January 13th. Royal Bank of Canada reissued a &#34;sector perform&#34; rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler reaffirmed a &#34;neutral&#34; rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Leerink Partnrs cut Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of &#34;Hold&#34; and a consensus target price of $106.23.</p>
<div class="lb-trans"><p>其他分析师最近也对该股票发布了报告。瑞穗证券将 Intra-Cellular Therapies 的股票评级从 “跑赢大盘” 下调至 “中性”，并在 2 月 24 日的研究报告中将其目标价从 140.00 美元下调至 132.00 美元。贝尔德 R W 在 1 月 13 日的研究报告中将 Intra-Cellular Therapies 的评级从 “强力买入” 下调至 “持有”。加拿大皇家银行在 1 月 22 日的报告中重新发布了 “行业表现” 评级，并将 Intra-Cellular Therapies 的目标价设定为 132.00 美元（上调自 108.00 美元）。派珀·桑德勒在 1 月 14 日的研究报告中重申了 “中性” 评级，并将 Intra-Cellular Therapies 的目标价上调至 132.00 美元（之前为 107.00 美元）。最后，Leerink Partners 在 1 月 13 日的研究报告中将 Intra-Cellular Therapies 的评级从 “强力买入” 下调至 “持有”。共有 11 位分析师对该股票给予了持有评级，5 位分析师给予了买入评级。根据 MarketBeat 的数据，Intra-Cellular Therapies 目前的平均评级为 “持有”，共识目标价为 106.23 美元。</p>
</div><p><strong>Get Our Latest Research Report on ITCI</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ITCI 的最新研究报告</strong></p>
</div><h2>Intra-Cellular Therapies Stock Performance</h2>
<div class="lb-trans"><h2>Intra-Cellular Therapies 股票表现</h2>
</div><ul>
<li>Is Johnson &amp; Johnson Stock Set to Reward Long-Term Holders?</li>
</ul>
<div class="lb-trans"><ul>
<li>强生股票是否准备回报长期持有者？</li>
</ul>
</div><p>NASDAQ ITCI opened at $131.87 on Friday. The business's fifty day moving average is $129.62 and its 200 day moving average is $101.43. Intra-Cellular Therapies has a fifty-two week low of $64.09 and a fifty-two week high of $131.98. The company has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.</p>
<div class="lb-trans"><p>NASDAQ ITCI 周五开盘价为 131.87 美元。该公司的 50 日移动平均线为 129.62 美元，200 日移动平均线为 101.43 美元。Intra-Cellular Therapies 的 52 周低点为 64.09 美元，52 周高点为 131.98 美元。该公司的市值为 140.5 亿美元，市盈率为 -151.57，贝塔值为 0.69。</p>
</div><p>Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, sell-side analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current year.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies (NASDAQ:ITCI - 获取免费报告) 最近在 2 月 21 日发布了季度财报。这家生物制药公司报告的每股收益为（0.16）美元，低于分析师的共识预期（0.08）美元，差距为（0.08）美元。该季度的收入为 1.9922 亿美元，而分析师的预期为 2.0508 亿美元。Intra-Cellular Therapies 的净利润率为 -14.07%，股本回报率为 -9.93%。平均而言，卖方分析师预测 Intra-Cellular Therapies 在当前年度的每股收益为 -0.64。</p>
</div><h2>Institutional Investors Weigh In On Intra-Cellular Therapies</h2>
<div class="lb-trans"><h2>机构投资者对 Intra-Cellular Therapies 的看法</h2>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的大额收购：在 2 笔生物技术交易中达 181 亿美元</li>
</ul>
</div><p>Several large investors have recently bought and sold shares of the business. MassMutual Private Wealth &amp; Trust FSB increased its holdings in shares of Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 133 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Intra-Cellular Therapies by 1.6% in the fourth quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company's stock valued at $86,338,000 after acquiring an additional 16,096 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Intra-Cellular Therapies by 36.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,010 shares of the biopharmaceutical company's stock valued at $1,003,000 after purchasing an additional 3,200 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth about $7,951,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth about $186,000. Institutional investors own 92.33% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了该公司的股票。MassMutual Private Wealth &amp; Trust FSB 在第一季度将其在 Intra-Cellular Therapies 的持股增加了 124.3%。MassMutual Private Wealth &amp; Trust FSB 目前拥有 240 股该生物制药公司的股票，价值 32,000 美元，此前在上个季度又购买了 133 股。威灵顿管理集团在第四季度将其在 Intra-Cellular Therapies 的持股增加了 1.6%。威灵顿管理集团目前拥有 1,033,743 股该生物制药公司的股票，价值 86,338,000 美元，此前在此期间又收购了 16,096 股。Wealth Enhancement Advisory Services LLC 在第四季度将其在 Intra-Cellular Therapies 的持股增加了 36.3%。Wealth Enhancement Advisory Services LLC 目前拥有 12,010 股该生物制药公司的股票，价值 1,003,000 美元，此前在上个季度又购买了 3,200 股。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度购买了 Intra-Cellular Therapies 的新股份，价值约 7,951,000 美元。最后，GF Fund Management CO. LTD. 在第四季度购买了 Intra-Cellular Therapies 的新股份，价值约 186,000 美元。机构投资者持有该公司 92.33% 的股票。</p>
</div><h2>About Intra-Cellular Therapies</h2>
<div class="lb-trans"><h2>关于 Intra-Cellular Therapies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies, Inc 是一家生物制药公司，专注于发现、临床开发和商业化小分子药物，主要针对神经精神和神经系统疾病的医疗需求，通过靶向美国中枢神经系统 (CNS) 的细胞内信号机制。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Intra-Cellular Therapies</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Intra-Cellular Therapies</li>
<li>投资旅游股票的好处</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>顶级生物技术股票：探索创新机会</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>电动车股票及其盈利方式</li>
<li>波音在 3 月获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ITCI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intra-Cellular Therapies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Intra-Cellular Therapies 吗？</h2>
</div><p>Before you consider Intra-Cellular Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Intra-Cellular Therapies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前... 而 Intra-Cellular Therapies 并不在名单上。</p>
</div><p>While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Intra-Cellular Therapies 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Intra-Cellular Therapies（纳斯达克股票代码：ITCI）获得 StockNews.com 分析师的持有评级